Expert review of anticancer therapy
-
Expert Rev Anticancer Ther · Aug 2016
Meta Analysis Comparative StudyDenosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis.
A mixed treatment analysis of the comparative effectiveness of denosumab versus zoledronic acid in the prevention of fractures in early postmenopausal breast cancer patients treated with aromatase inhibitors has been conducted. ⋯ This analysis demonstrated that in postmenopausal patients receiving adjuvant aromatase inhibitors, immediate denosumab decreases the risk of fractures compared to delayed treatment at the cutoff of 36 months. Immediate zoledronic acid, however, does not provide the same level of fractures' protection in this category of patients.